Platforms
Our platforms offer walk-away, sample-to-answer solutions for life science research, clinical research, and diagnosticsALPCO is a global leader in platforms for immunodiagnostics and molecular diagnostics. Our proprietary automated sample-to-answer solutions provide efficiency and ease-of-use for th...
Molecular Diagnostics
GeneProof Molecular Diagnostics Assays & InstrumentationManual and automated sample-to-answer solutions for PCR-based molecular diagnostics offering universal protocols, simplified workflows, and a wide range of testsmyCROBE Solution for Extraction, PCR, and automated evaluation of resultsThe my...
Multiplex Biomarker Instrumentation
Discover Automated Multiplex Testing to Simplify Batch AnalysisALPCO has partnered with DYNEX® Technologies to leverage the DYNEX Multiplier® powered by SmartPlex® technology to fully automate multiplex analysis of novel protein biomarkers.DYNEX Multiplier® Automated Chemiluminescence AnalyzerThe DY...
Flash chemi immunoassays & instruments
Flash
Chemiluminescence Assays on the KleeYa PlatformCombine the sensitivity and accuracy of ALPCO flash chemiluminescence assays with the efficiency of the KleeYa platform to streamline analysis for the tests that matter most.KleeYa
PlatformThe KleeYa platform is a fully automated random-access a...
ALPCO Releases STELLUX® Chemiluminescent Human Intact Proinsulin ELISA
ALPCO announced in a press release on February 18, 2014 that the company has launched their new STELLUX® Chemiluminescent Human Intact Proinsulin ELISA, the latest assay to be launched in the company’s STELLUX® Chemiluminescent product line. The new Human Intact Proinsulin ELISA features a broad dyn...
ALPCO Releases New Chemiluminescent Human C-peptide ELISA
ALPCO announced the launch of its new STELLUX® Chemiluminescent Human C-peptide ELISA on December 5, 2014. This highly characterized assay measures C-peptide requiring only 50 µL of human serum, plasma or cell culture supernatant. The ELISA exhibits greater sensitivity and a broader dynamic range co...
ALPCO and Cisbio US, Inc. Announce Sales and Distribution Agreement
Date: July 1, 2015
ALPCO is pleased to announce a strategic account sales and distribution agreement with Cisbio US, Inc. Cisbio will now have exclusive access to ALPCO’s high quality STELLUX® Chemiluminescence and colorimetric Diabetes and Obesity assay portfolio in order to provide these produc...
Customer Spotlight: Measuring Functionality of Islet Microtissues
Date: July 26, 2016
Beta cell generation has gained much traction in recent years among diabetes researchers. Investigators are not only converting adipose tissue and skin cells into beta cells, they are also starting to grow beta cells in a petri dish in vitro. Swiss company InSphero has begun m...
Introducing the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA
Watch our video to learn more about the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and how you can now measure this incretin hormone with confidence.
https://www.youtube.com/watch?v=Chu3VhEEpt0&t=3s
The STELLUX® Chemi Active GLP-1 (7-36) amide ELISA features increased sensitivity to ac...
An Accurate Solution to the Challenges with Measuring GLP-1
Glucagon-like peptide-1 (GLP-1) is a gut hormone which plays an essential role in insulin secretion and glucose homeostasis1. While GLP-1 has become central to many metabolic disease research programs, various GLP-1 ELISA kits currently available on the market have been failing to meet the needs of ...
How DPP-4 Complicates Measuring GLP-1 Accurately
We know that the proper collection and handling of samples is vital for eliminating analytical variability and improving accuracy when measuring active GLP-1 (7-36) amide.
ALPCO is here to help your lab reduce technical errors and improve assay results when running the STELLUX® Chemi Active GLP-1...
How to Properly Collect and Handle GLP-1 Samples
We know that the proper collection and handling of samples is vital for accurately measuring GLP-1.
ALPCO is here to help your lab reduce technical errors and improve assay results when running the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA.
Watch our video to learn how to properly collect...
A Guide to STELLUX® Chemiluminscence ELISAs: An Infographic
Today, multiple immunoassay platforms exist, providing scientists and clinicians with the means to measure a variety of biomarkers1,2,3. However, research indicates some immunoassay platforms have limitations that can inhibit progress in the laboratory4,5,6. In an effort to provide researchers with ...
A Comparison of Colorimetric and Chemiluminescence ELISAs
Are you curious about chemiluminescence ELISAs, but not exactly sure what they are, or how to use them? Our video A Comparison of Colorimetric and Chemiluminescence ELISAs discusses how similar these two types of assays are, and how they can enhance your lab testing.
Watch our video to:
Lear...
Now Available: 510(k) Cleared Fecal Calprotectin ELISA
ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test.
The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the cha...
ALPCO’s Calprotectin Validation Assistance Program
Whether your clinical laboratory is transitioning over to the ALPCO Calprotectin Chemiluminescence ELISA from another calprotectin assay or starting to run the test in-house for the first time, validation is the most crucial step in the assay implementation process. We understand that validating a n...
Celebrating Diabetes Research
In honor of scientists and researchers in the field of diabetes, we've compiled a partial list of their 2023 published work. These publications aren't just studies; they're milestones on the path to a healthier future, made possible by their dedication.
What makes this list so ...
Toxicology
Drug-Induced Organ Injury
Toxicological side effects are a common obstacle in drug development pipelines and often manifest in site-specific damage to vital organs, including the liver, kidney and heart. Estimates of compound attrition from failure to meet safety endpoints are as high as 45% in pre...